DeepMed Research

LigaChem Biosciences, Inc.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 2006-05-01

Employees: 147

Market Cap: -

Website: http://www.legochembio.com

Clinical Trials

Study to Evaluate the Efficacy of Delpazolid As Add-on Therapy in Refractory Mycobacterium Abscessus Complex

Phase 2

Recruiting

Conditions: Mycobacterium Abscessus Infection
Nontuberculous Mycobacterium Infection

Interventions: Drug: Delpazolid

First Posted Date: 2023-08-22

Last Posted Date: 2025-01-23

Lead Sponsor: LigaChem Biosciences, Inc.

Target Recruit Count: 20

Registration Number: NCT06004037

Locations: 🇰🇷
Bundang Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 2 locations

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: LCB84
Drug: Anti-PD-1 monoclonal antibody

First Posted Date: 2023-07-12

Last Posted Date: 2024-04-19

Lead Sponsor: LigaChem Biosciences, Inc.

Target Recruit Count: 300

Registration Number: NCT05941507

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 3 locations

A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia

Phase 2

Terminated

Conditions: MRSA Bacteremia

Interventions: Drug: Delpazolid
Drug: Vancomycin
Drug: Placebo of Delpazolid

First Posted Date: 2022-02-04

Last Posted Date: 2025-05-06

Lead Sponsor: LigaChem Biosciences, Inc.

Target Recruit Count: 40

Registration Number: NCT05225558

Locations: 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷
Chosun University Hospital, Gwangju, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of

and more 3 locations

Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
Drug: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)

First Posted Date: 2021-06-25

Last Posted Date: 2021-06-25

Lead Sponsor: LigaChem Biosciences, Inc.

Target Recruit Count: 25

Registration Number: NCT04939779

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)

Phase 2

Completed

Conditions: Infections and Infestations
Pulmonary Tuberculosis

Interventions: Drug: Bedaquiline, Delamanid, Moxifloxacin
Drug: Delpazolid

First Posted Date: 2020-09-16

Last Posted Date: 2024-10-28

Lead Sponsor: LigaChem Biosciences, Inc.

Target Recruit Count: 76

Registration Number: NCT04550832

Locations: 🇹🇿
Ifakara Health Institute, Bagamoyo, Tanzania
🇿🇦
The Aurum Institute Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa
🇿🇦
Clinical HIV Research Unit (CHRU) University of the Witwatersrand, Johannesburg, South Africa

and more 2 locations

A Mass Balance Study of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371-microtrace

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose

First Posted Date: 2018-04-10

Last Posted Date: 2021-03-12

Lead Sponsor: LigaChem Biosciences, Inc.

Target Recruit Count: 6

Registration Number: NCT03492996

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LCB01-0371
Drug: LCB01-0371 400mg

First Posted Date: 2016-08-30

Last Posted Date: 2018-04-10

Lead Sponsor: LigaChem Biosciences, Inc.

Target Recruit Count: 24

Registration Number: NCT02882789

Locations: 🇰🇷
Bae KS, Seoul, Korea, Republic of

A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: LCB01-0371 800mg, QD
Drug: LCB01-0371 1200mg, QD
Drug: Zyvox 600mg, BID
Drug: LCB01-0371 400mg, BID
Drug: LCB01-0371 800mg, BID
Drug: Tubes 3~5Tablet, QD

First Posted Date: 2016-07-19

Last Posted Date: 2020-02-06

Lead Sponsor: LigaChem Biosciences, Inc.

Target Recruit Count: 79

Registration Number: NCT02836483

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LCB01-0371 800mg
Drug: LCB01-0371 1200mg BID
Drug: Placebo
Drug: LCB01-0371 800mg BID

First Posted Date: 2015-09-04

Last Posted Date: 2015-09-04

Lead Sponsor: LigaChem Biosciences, Inc.

Target Recruit Count: 30

Registration Number: NCT02540460

Locations: 🇰🇷
Seoul National University Bundang Hospital, Bundang, Gyeonggi, Korea, Republic of

To Evaluate the Effect of Food on Pharmacokinetics(PK), Phase I Clinical Study of LCB01-0371

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LCB01-0371 Tablet 800 mg(R)
Drug: LCB01-0371 Tablet 800 mg(T)

First Posted Date: 2015-09-02

Last Posted Date: 2016-03-23

Lead Sponsor: LigaChem Biosciences, Inc.

Target Recruit Count: 30

Registration Number: NCT02538003

Locations: 🇰🇷
Seoul National University Bundang Hospital, Bundang, Gyeonggi, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy